Clinical Trial News and Research

RSS

Research shows how patient experiences can be used to improve healthcare

A research project led by Oxford University is showing how patient experiences can be used to improve healthcare - not through targets and surveys, but by getting doctors, nurses and patients talking together about care on the ward.

6 Mar 2014

Merck announces new data from ongoing C-WORTHY Study in HIV/HCV co-infected patients

Merck, known as MSD outside of the United States and Canada, today announced new data from HIV/HCV co-infected patients in the ongoing C-WORTHY Study, a Phase 2 clinical trial evaluating the efficacy and safety of Merck's all-oral, once-daily regimen combining MK-5172, an investigational hepatitis C virus (HCV) NS3/4A protease inhibitor, and MK-8742, an investigational HCV NS5A replication complex inhibitor.

5 Mar 2014

Agenus reports net loss attributable to common stockholders of $5.8 million for Q4 2013

Agenus Inc., a biopharmaceutical company developing a portfolio of immuno-oncology candidates, including checkpoint modulators (CPMs), heat shock protein vaccines and adjuvants, today announced its financial results and business highlights for the fourth quarter and year ended December 31, 2013.

5 Mar 2014

Kamada initiates Phase 2/3 clinical trial of Glassia to treat pediatric patients with T1D

Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces the initiation of a Phase 2/3 clinical trial of Glassia®, the Company's proprietary human Alpha-1 Antitrypsin (AAT), to treat newly diagnosed pediatric patients with type 1 diabetes (T1D).

5 Mar 2014

Curie-Cancer, DNA Therapeutics renew partnership to identify new class of cancer drugs

Curie-Cancer, the body responsible for developing Institut Curie’s industry partnership activities, and DNA Therapeutics, a biopharmaceutical company that is developing a new class of cancer drugs, are renewing their partnership.

5 Mar 2014

POZEN reports total revenue of $4.7 million for fourth quarter 2013

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, today announced results for the fourth quarter and year ended December 31, 2013.

5 Mar 2014

Eisai collaborates with Biogen Idec to develop and commercialize treatment options for AD

Eisai Co., Ltd. and Biogen Idec announced today that they have entered into a collaboration to develop and commercialize two of Eisai's clinical candidates for Alzheimer's disease (AD), E2609 and BAN2401.

5 Mar 2014

Experimental drug nivolumab shrinks tumors in patients with advanced melanoma

An experimental drug aimed at restoring the immune system's ability to spot and attack cancer halted cancer progression or shrank tumors in patients with advanced melanoma, according to a multisite, early-phase clinical trial at Johns Hopkins Kimmel Cancer Center and 11 other institutions. All patients had experienced disease progression despite prior systemic therapies, and most had received two or more prior treatments.

4 Mar 2014

AAA gets orphan drug designation status for radiopharmaceutical, Gallium-68 DOTATATE

Advanced Accelerator Applications (AAA), a fast growing international player in Molecular Nuclear Medicine (MNM), announced today that they have received orphan drug designation status for their radiopharmaceutical, Gallium-68 DOTATATE.

4 Mar 2014

Omeros submits investigational new drug to initiate OMS721 Phase 2 clinical program

Omeros Corporation today announced that it has submitted to the U.S. Food and Drug Administration (FDA) an investigational new drug (IND) application to initiate the Phase 2 clinical program for OMS721, the company's lead human monoclonal antibody targeting mannan-binding lectin‑associated serine protease-2 (MASP-2), the key regulator of the lectin pathway of the immune system.

4 Mar 2014

GTx provides clinical updates, reports financial results for fourth quarter and full year 2013

GTx, Inc. today provided a Company update and reported financial results for the fourth quarter and full year 2013.

4 Mar 2014

Rigel Pharmaceuticals reports net loss of $16.9 million for fourth quarter 2013

Rigel Pharmaceuticals, Inc. today reported financial results for the fourth quarter and year ended December 31, 2013.

4 Mar 2014

New AskRx version 1.0 enables patients to ask health and medication questions

RxWiki, Inc. announced today the launch of AskRx version 1.0, enabling patients to ask Digital Pharmacists™ health and medication questions.

4 Mar 2014

Drug that unleashes immune system can produce lasting remissions in patients with melanoma

A drug that unleashes the immune system to attack cancer can produce lasting remissions and hold the disease in check - for more than two years, in some cases - in many patients with advanced melanoma, according to a new study by researchers at Dana-Farber Cancer Institute, Johns Hopkins University, Yale University, and allied institutions.

4 Mar 2014

LFB SA initiates Phase 3 program for human Factor VIIa in patients with congenital hemophilia

LFB SA, through its rEVO Biologics subsidiary, announced today initiation of the global Phase 3 program for LR769, a novel recombinant form of human Factor VIIa, in patients with congenital hemophilia A or B with inhibitors.

4 Mar 2014

AcelRx Pharmaceuticals announces financial results for fourth quarter and full year 2013

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported financial results for the three and twelve months ended December 31, 2013.

4 Mar 2014

Arrowhead receives approval to initiate Phase 2a clinical trial of ARC-520 for chronic HBV infection

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it received regulatory approval to begin a Phase 2a clinical trial of ARC-520, its RNAi-based drug candidate for the treatment of chronic hepatitis B virus (HBV) infection.

4 Mar 2014

Intra-Cellular Therapies initiates Phase I/II clinical trial to evaluate pharmacokinetics in patients with dementia

Intra-Cellular Therapies, Inc., a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced the initiation of ITI-007-200, a Phase I/II clinical trial designed to evaluate the safety, tolerability and pharmacokinetics of low doses of its lead drug candidate, ITI-007, in healthy geriatric subjects and in patients with dementia, including Alzheimer's disease.

4 Mar 2014

New findings point the way toward potentially more effective HIV vaccine

In an advance for HIV vaccine research, a scientific team has discovered how the immune system makes a powerful antibody that blocks HIV infection of cells by targeting a site on the virus called V1V2.

4 Mar 2014

OPKO Health consolidated revenues increase about 30% to $20.7 million in Q4 2013

OPKO Health, Inc., a multi-national biopharmaceutical and diagnostics company, today reported operating and financial results for its 2013 fourth quarter and full year ended December 31, 2013.

4 Mar 2014

Clinical Trial News and Research

Research shows how patient experiences can be used to improve healthcare

Merck announces new data from ongoing C-WORTHY Study in HIV/HCV co-infected patients

Agenus reports net loss attributable to common stockholders of $5.8 million for Q4 2013

Kamada initiates Phase 2/3 clinical trial of Glassia to treat pediatric patients with T1D

Curie-Cancer, DNA Therapeutics renew partnership to identify new class of cancer drugs

POZEN reports total revenue of $4.7 million for fourth quarter 2013

Eisai collaborates with Biogen Idec to develop and commercialize treatment options for AD

Experimental drug nivolumab shrinks tumors in patients with advanced melanoma

AAA gets orphan drug designation status for radiopharmaceutical, Gallium-68 DOTATATE

Omeros submits investigational new drug to initiate OMS721 Phase 2 clinical program

GTx provides clinical updates, reports financial results for fourth quarter and full year 2013

Rigel Pharmaceuticals reports net loss of $16.9 million for fourth quarter 2013

New AskRx version 1.0 enables patients to ask health and medication questions

Drug that unleashes immune system can produce lasting remissions in patients with melanoma

LFB SA initiates Phase 3 program for human Factor VIIa in patients with congenital hemophilia

AcelRx Pharmaceuticals announces financial results for fourth quarter and full year 2013

Arrowhead receives approval to initiate Phase 2a clinical trial of ARC-520 for chronic HBV infection

Intra-Cellular Therapies initiates Phase I/II clinical trial to evaluate pharmacokinetics in patients with dementia

New findings point the way toward potentially more effective HIV vaccine

OPKO Health consolidated revenues increase about 30% to $20.7 million in Q4 2013

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Editorial Focus eBook - Proteomics (2nd Edition)

Industry Focus eBook - Life Science Microscopy (2nd Edition)

Biologics stability screening toolkit: Three practical workflows for accelerating formulation development

Event guide: 2nd World RNA-Based Therapeutics & Vaccines Summit Korea

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery